This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs
Translational Psychiatry Open Access 01 March 2023
-
“Digital biomarkers” in preclinical heart failure models — a further step towards improved translational research
Heart Failure Reviews Open Access 24 August 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arrowsmith, J. Phase II failures: 2008–2010. Nat Rev Drug Discov 10, 328–329 (2011). https://doi.org/10.1038/nrd3439
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3439
This article is cited by
-
A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia
Advances in Therapy (2024)
-
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs
Translational Psychiatry (2023)
-
An effector index to predict target genes at GWAS loci
Human Genetics (2022)
-
“Digital biomarkers” in preclinical heart failure models — a further step towards improved translational research
Heart Failure Reviews (2022)